These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3211 related articles for article (PubMed ID: 25043833)

  • 21. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
    Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
    J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.
    Chiotis K; Carter SF; Farid K; Savitcheva I; Nordberg A;
    Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1492-506. PubMed ID: 26130168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.
    Bailly M; Ribeiro MJ; Vercouillie J; Hommet C; Gissot V; Camus V; Guilloteau D
    Clin Nucl Med; 2015 Feb; 40(2):e111-6. PubMed ID: 25549345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlations between atrophy of the entorhinal cortex and cognitive function in patients with Alzheimer's disease and mild cognitive impairment.
    Li X; Jiao J; Shimizu S; Jibiki I; Watanabe K; Kubota T
    Psychiatry Clin Neurosci; 2012 Dec; 66(7):587-93. PubMed ID: 23252925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
    Yew B; Nation DA;
    Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations between quantitative [
    Timmers T; Ossenkoppele R; Wolters EE; Verfaillie SCJ; Visser D; Golla SSV; Barkhof F; Scheltens P; Boellaard R; van der Flier WM; van Berckel BNM
    Alzheimers Res Ther; 2019 Jul; 11(1):60. PubMed ID: 31272512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease.
    Fleisher AS; Chen K; Liu X; Ayutyanont N; Roontiva A; Thiyyagura P; Protas H; Joshi AD; Sabbagh M; Sadowsky CH; Sperling RA; Clark CM; Mintun MA; Pontecorvo MJ; Coleman RE; Doraiswamy PM; Johnson KA; Carpenter AP; Skovronsky DM; Reiman EM
    Neurobiol Aging; 2013 Jan; 34(1):1-12. PubMed ID: 22633529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
    Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
    J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
    Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
    J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tau PET in Alzheimer disease and mild cognitive impairment.
    Cho H; Choi JY; Hwang MS; Lee JH; Kim YJ; Lee HM; Lyoo CH; Ryu YH; Lee MS
    Neurology; 2016 Jul; 87(4):375-83. PubMed ID: 27358341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
    Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
    J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
    Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
    PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.
    Landau SM; Horng A; Fero A; Jagust WJ;
    Neurology; 2016 Apr; 86(15):1377-1385. PubMed ID: 26968515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Precuneus - A Witness for Excessive Aβ Gathering in Alzheimer's Disease Pathology.
    Aghakhanyan G; Vergallo A; Gennaro M; Mazzarri S; Guidoccio F; Radicchi C; Ceravolo R; Tognoni G; Bonuccelli U; Volterrani D
    Neurodegener Dis; 2018; 18(5-6):302-309. PubMed ID: 30814473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment.
    Mattsson N; Tosun D; Insel PS; Simonson A; Jack CR; Beckett LA; Donohue M; Jagust W; Schuff N; Weiner MW;
    Brain; 2014 May; 137(Pt 5):1550-61. PubMed ID: 24625697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 161.